Malignant stroma increases luminal breast cancer cell proliferation and angiogenesis through platelet-derived growth factor signaling

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Pinto, Mauricio P ^a,c   Dye, Wendy W ^a   Jacobsen, Britta M ^b   Horwitz, Kathryn B ^a,b  

^a University of Medicine   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSIDAD ANDRÉS BELLO   (Chile)

Author keywords

Angiogenesis; Breast cancer; Proliferation; Stroma

Indexed keywords

IMATINIB; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TRANSCRIPTOME;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; BJ3Z CELL LINE; BREAST CANCER; BT 20 CELL LINE; BT 474 CELL LINE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MCF 7 CELL LINE; MDA MB 231 CELL LINE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STROMA CELL; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; FEMALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; TUMOR MICROENVIRONMENT;

ANIMALS; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; FIBROBLASTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MCF-7 CELLS; MICE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-DERIVED GROWTH FACTOR; STROMAL CELLS; TRANSCRIPTOME; TUMOR MICROENVIRONMENT;

EID: 84907961807     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-735     Document Type: Article

References (72)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752. 10.1038/35021093, 10963602.
2. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 2006, 295(21):2492-2502. 10.1001/jama.295.21.2492, 16757721.
3. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378(9793):771-784. 3163848, 21802721.
4. Palmieri C, Patten DK, Januszewski A, Zucchini G, Howell SJ. Breast cancer: current and future endocrine therapies. Mol Cell Endocrinol 2014, 382(1):695-723. 10.1016/j.mce.2013.08.001, 23933149.
5. Goubran HA, Kotb RR, Stakiw J, Emara ME, Burnouf T. Regulation of tumor growth and metastasis: the role of tumor microenvironment. Cancer growth and metastasis 2014, 7:9-18. 4051818, 24926201.
6. Mao Y, Keller ET, Garfield DH, Shen K, Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 2013, 32(1-2):303-315.
7. Shekhar MP, Santner S, Carolin KA, Tait L. Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. Am J Pathol 2007, 170(5):1546-1560. 10.2353/ajpath.2007.061004, 1854950, 17456761.
8. Martinez-Outschoorn UE, Goldberg A, Lin Z, Ko YH, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, Lisanti MP. Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther 2011, 12(10):924-938. 10.4161/cbt.12.10.17780, 3280908, 22041887.
9. Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 2003, 3(5):439-443. 10.1016/S1535-6108(03)00089-8, 12781361.
10. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008, 22(10):1276-1312. 10.1101/gad.1653708, 2732412, 18483217.
11. Cao Y, Cao R, Hedlund EM. R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J Mol Med (Berl) 2008, 86(7):785-789. 10.1007/s00109-008-0337-z, 18392794.
12. Ross R, Glomset J, Kariya B, Harker L. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci U S A 1974, 71(4):1207-1210. 10.1073/pnas.71.4.1207, 388193, 4208546.
13. Heldin CH, Westermark B. Platelet-derived growth factor: mechanism of action and possible in vivo function. Cell Regul 1990, 1(8):555-566. 361590, 1964089.
14. Demoulin JB, Essaghir A. PDGF receptor signaling networks in normal and cancer cells. Cytokine Growth Factor Rev 2014, 25(3):273-283. 10.1016/j.cytogfr.2014.03.003, 24703957.
15. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 2004, 15(4):275-286. 10.1016/j.cytogfr.2004.03.002, 15207817.
16. Heldin CH. Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signaling 2013, 11:97.
17. Kubler HR, van Randenborgh H, Treiber U, Wutzler S, Battistel C, Lehmer A, Wagenpfeil S, Hartung R, Paul R. In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. Prostate 2005, 63(4):385-394. 10.1002/pros.20201, 15617027.
18. Annunziata M, Luque RM, Duran-Prado M, Baragli A, Grande C, Volante M, Gahete MD, Deltetto F, Camanni M, Ghigo E, Castaño JP, Granata R. Somatostatin and somatostatin analogues reduce PDGF-induced endometrial cell proliferation and motility. Hum Reprod 2012, 27(7):2117-2129. 10.1093/humrep/des144, 22588000.
19. Taeger J, Moser C, Hellerbrand C, Mycielska ME, Glockzin G, Schlitt HJ, Geissler EK, Stoeltzing O, Lang SA. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther 2011, 10(11):2157-2167. 10.1158/1535-7163.MCT-11-0312, 21885862.
20. Kinoshita K, Nakagawa K, Hamada J, Hida Y, Tada M, Kondo S, Moriuchi T. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells. Int J Oncol 2010, 37(4):869-877.
21. Chen YC, Chang CN, Hsu HC, Chiou SJ, Lee LT, Hseu TH. Sennoside B inhibits PDGF receptor signaling and cell proliferation induced by PDGF-BB in human osteosarcoma cells. Life Sci 2009, 84(25-26):915-922.
22. Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, Donovan M, Cordon-Cardo C, Beug H, Grunert S. Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 2006, 116(6):1561-1570. 10.1172/JCI24652, 1469776, 16741576.
23. Malavaki CJ, Roussidis AE, Gialeli C, Kletsas D, Tsegenidis T, Theocharis AD, Tzanakakis GN, Karamanos NK. Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells. FEBS J 2013, 280(10):2477-2489. 10.1111/febs.12163, 23374223.
24. Walker RA. The complexities of breast cancer desmoplasia. Breast Cancer Res 2001, 3(3):143-145. 10.1186/bcr287, 138677, 11305947.
25. Shao ZM, Nguyen M, Barsky SH. Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 2000, 19(38):4337-4345. 10.1038/sj.onc.1203785, 10980609.
26. Pasanisi P, Venturelli E, Morelli D, Fontana L, Secreto G, Berrino F. Serum insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis. Cancer Epidemiol Biomarkers Prev 2008, 17(7):1719-1722. 10.1158/1055-9965.EPI-07-0654, 18628423.
27. Jacobsen BM, Harrell JC, Jedlicka P, Borges VF, Varella-Garcia M, Horwitz KB. Spontaneous fusion with, and transformation of mouse stroma by, malignant human breast cancer epithelium. Cancer Res 2006, 66(16):8274-8279. 10.1158/0008-5472.CAN-06-1456, 16912208.
28. Pinto MP, Badtke MM, Dudevoir ML, Harrell JC, Jacobsen BM, Horwitz KB. Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptor-positive breast cancer. Cancer Res 2010, 70(7):2655-2664. 10.1158/0008-5472.CAN-09-4373, 2848872, 20332242.
29. Stuelten CH, DaCosta BS, Arany PR, Karpova TS, Stetler-Stevenson WG, Roberts AB. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. J Cell Sci 2005, 118(Pt 10):2143-2153.
30. Pinto MP, Jacobsen BM, Horwitz KB. An immunohistochemical method to study breast cancer cell subpopulations and their growth regulation by hormones in three-dimensional cultures. Front Endocrinol 2011, 2:15.
31. Weigel MT, Dahmke L, Schem C, Bauerschlag DO, Weber K, Niehoff P, Bauer M, Strauss A, Jonat W, Maass N, Mundhenke C. In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells. BMC Cancer 2010, 10:412. 10.1186/1471-2407-10-412, 2925350, 20691121.
32. Jacks T, Weinberg RA. Taking the study of cancer cell survival to a new dimension. Cell 2002, 111(7):923-925. 10.1016/S0092-8674(02)01229-1, 12507419.
33. Birgersdotter A, Baumforth KR, Porwit A, Sundblad A, Falk KI, Wei W, Sjoberg J, Murray PG, Bjorkholm M, Ernberg I. Three-dimensional culturing of the Hodgkin lymphoma cell-line L1236 induces a HL tissue-like gene expression pattern. Leuk Lymphoma 2007, 48(10):2042-2053. 10.1080/10428190701573190, 17917972.
34. Brown KJ, Maynes SF, Bezos A, Maguire DJ, Ford MD, Parish CR. A novel in vitro assay for human angiogenesis. Lab Invest 1996, 75(4):539-555.
35. Donovan D, Brown NJ, Bishop ET, Lewis CE. Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo. Angiogenesis 2001, 4(2):113-121. 10.1023/A:1012218401036, 11806243.
36. Arendt LM, Rudnick JA, Keller PJ, Kuperwasser C. Stroma in breast development and disease. Semin Cell Dev Biol 2010, 21(1):11-18. 10.1016/j.semcdb.2009.10.003, 2823823, 19857593.
37. Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr Opin Genet Dev 2005, 15(1):97-101. 10.1016/j.gde.2004.12.003, 2819733, 15661539.
38. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121(3):335-348. 10.1016/j.cell.2005.02.034, 15882617.
39. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006, 6(5):392-401. 10.1038/nrc1877, 16572188.
40. Camp JT, Elloumi F, Roman-Perez E, Rein J, Stewart DA, Harrell JC, Perou CM, Troester MA. Interactions with fibroblasts are distinct in Basal-like and luminal breast cancers. Mol Cancer Res 2011, 9(1):3-13. 10.1158/1541-7786.MCR-10-0372, 3045848, 21131600.
41. Weigel MT, Banerjee S, Arnedos M, Salter J, AHern R, Dowsett M, Martin LA. Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer. Ann Oncol 2013, 24(1):126-133. 10.1093/annonc/mds240, 22865780.
42. Rocha A, Azevedo I, Soares R. Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects. J Cell Biochem 2008, 103(2):607-614. 10.1002/jcb.21432, 17614352.
43. Furuhashi M, Sjoblom T, Abramsson A, Ellingsen J, Micke P, Li H, Bergsten-Folestad E, Eriksson U, Heuchel R, Betsholtz C, Heldin CH, Ostman A. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res 2004, 64(8):2725-2733. 10.1158/0008-5472.CAN-03-1489, 15087386.
44. Sundberg C, Branting M, Gerdin B, Rubin K. Tumor cell and connective tissue cell interactions in human colorectal adenocarcinoma. Transfer of platelet-derived growth factor-AB/BB to stromal cells. Am J Pathol 1997, 151(2):479-492. 1857991, 9250160.
45. Kawai T, Hiroi S, Torikata C. Expression in lung carcinomas of platelet-derived growth factor and its receptors. Lab Invest 1997, 77(5):431-436.
46. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Hamilton SR, Fidler IJ. Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential. Int J Cancer 2006, 119(11):2567-2574. 10.1002/ijc.22229, 16988946.
47. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 2008, 5(1):e19. 10.1371/journal.pmed.0050019, 2214790, 18232728.
48. Bhardwaj B, Klassen J, Cossette N, Sterns E, Tuck A, Deeley R, Sengupta S, Elliott B. Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma. Clin Cancer Res 1996, 2(4):773-782.
49. Rykala J, Przybylowska K, Majsterek I, Pasz-Walczak G, Sygut A, Dziki A, Kruk-Jeromin J. Angiogenesis markers quantification in breast cancer and their correlation with clinicopathological prognostic variables. Pathol Oncol Res 2011, 17(4):809-817. 10.1007/s12253-011-9387-6, 3185224, 21560015.
50. Zhu L, Loo WT, Cheng CW, Chow LW. Possible predictive markers related to micro-metastasis in breast cancer patients. Oncol Rep 2006, 15(5):1217-1223.
51. Weigel MT, Ghazoui Z, Dunbier A, Pancholi S, Dowsett M, Martin LA. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. Breast Cancer Res 2012, 14(3):R78. 10.1186/bcr3191, 3446341, 22608253.
52. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674. 10.1016/j.cell.2011.02.013, 21376230.
53. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100(1):57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
54. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK, Seed B. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998, 94(6):715-725. 10.1016/S0092-8674(00)81731-6, 9753319.
55. Hughes CC. Endothelial-stromal interactions in angiogenesis. Curr Opin Hematol 2008, 15(3):204-209. 10.1097/MOH.0b013e3282f97dbc, 18391786.
56. Skobe M, Fusenig NE. Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc Natl Acad Sci U S A 1998, 95(3):1050-1055. 10.1073/pnas.95.3.1050, 18668, 9448283.
57. Guo P, Hu B, Gu W, Xu L, Wang D, Huang HJ, Cavenee WK, Cheng SY. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 2003, 162(4):1083-1093. 10.1016/S0002-9440(10)63905-3, 1851242, 12651601.
58. Kallergi G, Markomanolaki H, Giannoukaraki V, Papadaki MA, Strati A, Lianidou ES, Georgoulias V, Mavroudis D, Agelaki S. Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res 2009, 11(6):R84. 10.1186/bcr2452, 2815547, 19919679.
59. Hoch RV, Soriano P. Roles of PDGF in animal development. Development 2003, 130(20):4769-4784. 10.1242/dev.00721, 12952899.
60. Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev 2004, 15(4):215-228. 10.1016/j.cytogfr.2004.03.005, 15207813.
61. Chantrain CF, Henriet P, Jodele S, Emonard H, Feron O, Courtoy PJ, DeClerck YA, Marbaix E. Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases. Eur J Cancer 2006, 42(3):310-318. 10.1016/j.ejca.2005.11.010, 16406506.
62. Song N, Huang Y, Shi H, Yuan S, Ding Y, Song X, Fu Y, Luo Y. Overexpression of platelet-derived growth factor-BB increases tumor pericyte content via stromal-derived factor-1alpha/CXCR4 axis. Cancer Res 2009, 69(15):6057-6064. 10.1158/0008-5472.CAN-08-2007, 19584297.
63. Shaheen RM, Tseng WW, Davis DW, Liu W, Reinmuth N, Vellagas R, Wieczorek AA, Ogura Y, McConkey DJ, Drazan KE, Bucana CD, McMahon G, Ellis LM. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res 2001, 61(4):1464-1468.
64. Reinmuth N, Liu W, Jung YD, Ahmad SA, Shaheen RM, Fan F, Bucana CD, McMahon G, Gallick GE, Ellis LM. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J 2001, 15(7):1239-1241.
65. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111(9):1287-1295. 10.1172/JCI200317929, 154450, 12727920.
66. Piccaluga PP, Rondoni M, Paolini S, Rosti G, Martinelli G, Baccarani M. Imatinib mesylate in the treatment of hematologic malignancies. Expert Opin Biol Ther 2007, 7(10):1597-1611. 10.1517/14712598.7.10.1597, 17916051.
67. Krystal GW. Imatinib mesylate (STI571) for myeloid malignancies other than CML. Leuk Res 2004, 28(Suppl 1):S53-59.
68. Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, Birenbaum M, Bakhanashvili M, Yerushalmi R, Luria D, Lahav M. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer 2005, 92(10):1881-1891. 10.1038/sj.bjc.6602592, 2361771, 15870711.
69. Hiraga T, Nakamura H. Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals. Int J Cancer 2009, 124(1):215-222. 10.1002/ijc.23903, 18814279.
70. Lev DC, Kim SJ, Onn A, Stone V, Nam DH, Yazici S, Fidler IJ, Price JE. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin Cancer Res 2005, 11(1):306-314.
71. Chew HK, Barlow WE, Albain K, Lew D, Gown A, Hayes DF, Gralow J, Hortobagyi GN, Livingston R. A phase II study of Imatinib mesylate and capecitabine in metastatic breast cancer: southwest oncology group study 0338. Clin Breast Cancer 2008, 8(6):511-515. 10.3816/CBC.2008.n.062, 3510680, 19073506.
72. Yardley DA, Burris HA, Markus T, Spigel DR, Greco FA, Mainwaring M, Waterhouse DM, Webb CD, Hainsworth JD. Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer. Clin Breast Cancer 2009, 9(4):237-242. 10.3816/CBC.2009.n.040, 19933079.